227 related articles for article (PubMed ID: 28255749)
21. The correlation of Ki-67 staining indices with tumour doubling times in regrowing non-functioning pituitary adenomas.
Ekramullah SM; Saitoh Y; Arita N; Ohnishi T; Hayakawa T
Acta Neurochir (Wien); 1996; 138(12):1449-55. PubMed ID: 9030353
[TBL] [Abstract][Full Text] [Related]
22. Cell proliferation parameters and apoptosis indices in pituitary macroadenomas.
Ruggeri RM; Costa G; Simone A; Campennì A; Sindoni A; Ieni A; Cavallari V; Trimarchi F; Curtò L
J Endocrinol Invest; 2012 May; 35(5):473-8. PubMed ID: 21897111
[TBL] [Abstract][Full Text] [Related]
23. Clinical and Pathologic Characteristics Predicted the Postoperative Recurrence and Progression of Pituitary Adenoma: A Retrospective Study with 10 Years Follow-Up.
Lv L; Yin S; Zhou P; Hu Y; Chen C; Ma W; Jiang Y; Wang Z; Jiang S
World Neurosurg; 2018 Oct; 118():e428-e435. PubMed ID: 29981466
[TBL] [Abstract][Full Text] [Related]
24. Prothymosin-alpha and Ki-67 expression in pituitary adenomas.
Wierzbicka-Tutka I; Sokołowski G; Bałdys-Waligórska A; Adamek D; Radwańska E; Gołkowski F
Postepy Hig Med Dosw (Online); 2016 Nov; 70(0):1117-1123. PubMed ID: 27892895
[TBL] [Abstract][Full Text] [Related]
25. Treatment of clinically nonfunctioning pituitary adenomas with dopamine agonists.
Greenman Y; Cooper O; Yaish I; Robenshtok E; Sagiv N; Jonas-Kimchi T; Yuan X; Gertych A; Shimon I; Ram Z; Melmed S; Stern N
Eur J Endocrinol; 2016 Jul; 175(1):63-72. PubMed ID: 27150495
[TBL] [Abstract][Full Text] [Related]
26. Recurrences of Pituitary Adenomas or Second De Novo Tumors: Comparisons with First Tumors.
Saeger W; Müller M; Buslei R; Flitsch J; Fahlbusch R; Buchfelder M; Knappe UJ; Crock PA; Lüdecke DK
World Neurosurg; 2018 Nov; 119():e118-e124. PubMed ID: 30026158
[TBL] [Abstract][Full Text] [Related]
27. The Prognostic Roles of the Ki-67 Proliferation Index, P53 Expression, Mitotic Index, and Radiological Tumor Invasion in Pituitary Adenomas.
Hasanov R; Aydoğan Bİ; Kiremitçi S; Erden E; Güllü S
Endocr Pathol; 2019 Mar; 30(1):49-55. PubMed ID: 30610566
[TBL] [Abstract][Full Text] [Related]
28. Beta human chorionic gonadotropin (beta-hCG) expression in pituitary adenomas: relationship to endocrine function and tumour recurrence.
Doyle PM; Thiryayi WA; Joshi A; du Plessis D; Kearney T; Gnanalingham KK
Pituitary; 2009; 12(3):190-5. PubMed ID: 19005764
[TBL] [Abstract][Full Text] [Related]
29. Implications of the World Health Organization definition of atypia on surgically treated functional and non-functional pituitary adenomas.
Sarkar S; Philip VJ; Cherukuri SK; Chacko AG; Chacko G
Acta Neurochir (Wien); 2017 Nov; 159(11):2179-2186. PubMed ID: 28573325
[TBL] [Abstract][Full Text] [Related]
30. Immunohistochemical Study of NR2C2, BTG2, TBX19, and CDK2 Expression in 31 Paired Primary/Recurrent Nonfunctioning Pituitary Adenomas.
Yao X; Zhang Y; Wu L; Cheng R; Li C; Qu C; Ji H
Int J Endocrinol; 2019; 2019():5731639. PubMed ID: 31223310
[TBL] [Abstract][Full Text] [Related]
31. Epidrug mediated re-expression of miRNA targeting the HMGA transcripts in pituitary cells.
Kitchen MO; Yacqub-Usman K; Emes RD; Richardson A; Clayton RN; Farrell WE
Pituitary; 2015 Oct; 18(5):674-84. PubMed ID: 25557289
[TBL] [Abstract][Full Text] [Related]
32. Pituitary tumour transforming gene (PTTG) expression correlates with the proliferative activity and recurrence status of pituitary adenomas: a clinical and immunohistochemical study.
Filippella M; Galland F; Kujas M; Young J; Faggiano A; Lombardi G; Colao A; Meduri G; Chanson P
Clin Endocrinol (Oxf); 2006 Oct; 65(4):536-43. PubMed ID: 16984249
[TBL] [Abstract][Full Text] [Related]
33. Predicting recurrence of nonfunctioning pituitary adenomas.
Noh TW; Jeong HJ; Lee MK; Kim TS; Kim SH; Lee EJ
J Clin Endocrinol Metab; 2009 Nov; 94(11):4406-13. PubMed ID: 19820025
[TBL] [Abstract][Full Text] [Related]
34. Subcellular localization of basic fibroblast growth factor and fibroblast growth factor receptor 1 in pituitary adenomas.
Fukui S; Otani N; Nawashiro H; Yano A; Nomura N; Miyazawa T; Ohnuki A; Tsuzuki N; Katoh H; Ishihara S; Shima K
Brain Tumor Pathol; 2002; 19(1):23-9. PubMed ID: 12455885
[TBL] [Abstract][Full Text] [Related]
35. Tumor Recurrence or Regrowth in Adults With Nonfunctioning Pituitary Adenomas Using GH Replacement Therapy.
van Varsseveld NC; van Bunderen CC; Franken AA; Koppeschaar HP; van der Lely AJ; Drent ML
J Clin Endocrinol Metab; 2015 Aug; 100(8):3132-9. PubMed ID: 26057181
[TBL] [Abstract][Full Text] [Related]
36. The natural history of surgically treated but radiotherapy-naïve nonfunctioning pituitary adenomas.
O'Sullivan EP; Woods C; Glynn N; Behan LA; Crowley R; O'Kelly P; Smith D; Thompson CJ; Agha A
Clin Endocrinol (Oxf); 2009 Nov; 71(5):709-14. PubMed ID: 19302582
[TBL] [Abstract][Full Text] [Related]
37. Estrogen Receptor α, a Sex-Dependent Predictor of Aggressiveness in Nonfunctioning Pituitary Adenomas: SSTR and Sex Hormone Receptor Distribution in NFPA.
Øystese KA; Casar-Borota O; Normann KR; Zucknick M; Berg JP; Bollerslev J
J Clin Endocrinol Metab; 2017 Sep; 102(9):3581-3590. PubMed ID: 28911153
[TBL] [Abstract][Full Text] [Related]
38. Differential gene expression of sirtuins between somatotropinomas and nonfunctioning pituitary adenomas.
Grande IPP; Amorim PVGH; Freire ACTB; Jallad RS; Musolino NR; Cescato VA; da Silva GO; Bronstein MD; Trarbach EB
Pituitary; 2018 Aug; 21(4):355-361. PubMed ID: 29564694
[TBL] [Abstract][Full Text] [Related]
39. The Likelihood of Remnant Nonfunctioning Pituitary Adenomas Shrinking Is Associated with the Lesion's Blood Supply Pattern.
Ito M; Kuge A; Matsuda KI; Sato S; Kayama T; Sonoda Y
World Neurosurg; 2017 Nov; 107():137-141. PubMed ID: 28780404
[TBL] [Abstract][Full Text] [Related]
40. A Novel Invasive-Related Biomarker in Three Subtypes of Nonfunctioning Pituitary Adenomas.
Chen Y; Chuan HL; Yu SY; Li CZ; Wu ZB; Li GL; Zhang YZ
World Neurosurg; 2017 Apr; 100():514-521. PubMed ID: 28093347
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
